tbuckley/cabot-search huggingface dataset:
Bcl-2 proteins expression and response to navitoclax in platinum resistant/refractory recurrent ovarian cancer (PROC)
Authors: P.E. Brachet, F. Joly Lobbedez, M. Fabbro, A. Leary, J. Medioni, P. Follana, A.F. Lesoin, J.-S. Frenel, S. Abadie Lacourtoisie, A. Floquet, L. Gladieff, B. You, C. Gavoille, E. Kalbacher, M. Briand, P.A. Just, C. Blanc-Fournier, F. Giffard, B. Clarisse, L. Poulain
Journal: Annals of Oncology (2018)
P2.01-87 Profiling the Symptom Burden of Patients with Metastatic NSCLC Receiving Either Chemotherapy or Targeted Therapy: Real-World Data
Authors: Q. Shi, L. Williams, V. Vaghani, M. Hirschmann, L.L. Landry, E. Roarty, J. Zhang, W. Rinsurnogkawong, J. Lewis, C. Cleeland, J. Lee, J.A. Jack A. Roth, S. Swisher, J. Heymach, G. Simon
Journal: Journal of Thoracic Oncology (2018)
OA13.01 The Impact of [18F]fludeoxyglucose PET/CT in Small-Cell Lung Cancer: Analysis of the Phase 3 CONVERT Trial
Authors: P. Manorharan, A. Salem, H. Mistry, M. Gornall, S. Harden, P. Julyan, I. Locke, J. Mcaleese, R. Mcmenemin, N. Mohammed, M. Snee, T. Westwood, S. Woods, C. Faivre-Finn
Journal: Journal of Thoracic Oncology (2018)
P1.01-58 Variants Distribution and Heterogeneity of Outcomes to Crizotinib in ALK-Rearranged Chinese Non-Small Cell Lung Cancers
Authors: N. Liang, P. Xing, Y. Su, X. Long, Y. Gao, P. Chen, H. Liu, T. Zhang, B. Li, L. Zhang, X. Mao, Z. Zhang, J. Liu
Journal: Journal of Thoracic Oncology (2018)
Ribociclib (RIB) + fulvestrant (FUL) for advanced breast cancer (ABC): Progression-free survival (PFS) subgroup and tumor response analyses from MONALEESA-3
Authors: G. Jerusalem, P.A. Fasching, M. Martín, X. Pivot, K. Petrakova, G.V. Bianchi, A. Nusch, G.S. Sonke, L. De La Cruz Merino, E. Vagnon, J. Alam, O. Kong, D. Chandiwana, M. De Laurentiis
Journal: Annals of Oncology (2018)
Pain and quality of life in metastasized Castration Resistant Prostate Cancer patients treated with Radium-223 (ROTOR registry): A prospective observational registry in a non-study population
Authors: R. Louhanepessy, S. Badrising, V. Vd Noort, J.L. Coenen, A. Oostdijk, P. Hamberg, J.M. Zuetenhorst, A. Beeker, N. Wagenaar, M. Lam, F. Celik, E. Vegt, W. Zwart, A. Bergman
Journal: Annals of Oncology (2018)
Microbial Transplantation With Human Gut Commensals Containing CutC Is Sufficient to Transmit Enhanced Platelet Reactivity and Thrombosis Potential
Authors: Sarah M. Skye, Weifei Zhu, Kymberleigh A. Romano, Chun-Jun Guo, Zeneng Wang, Xun Jia, Jennifer Kirsop, Bridget Haag, Jennifer M. Lang, Joseph A. DiDonato, W.H. Wilson Tang, Aldons J. Lusis, Federico E. Rey, Michael A. Fischbach, Stanley L. Hazen
Journal: Circulation Research (2018)

Gut microbes influence cardiovascular disease and thrombosis risks through the production of trimethylamine N-oxide (TMAO). Microbiota-dependent generation of trimethylamine (TMA)-the precursor to TMAO-is rate limiting in the metaorganismal TMAO pathway in most humans and is catalyzed by several distinct microbial choline TMA-lyases, including the proteins encoded by the cutC/D (choline utilization C/D) genes in multiple human commensals.Direct demonstration that the gut microbial cutC gene is sufficient to transmit enhanced platelet reactivity and thrombosis potential in a host via TMA/TMAO generation has not yet been reported.Herein, we use gnotobiotic mice and a series of microbial colonization studies to show that microbial cutC-dependent TMA/TMAO production is sufficient to transmit heightened platelet reactivity and thrombosis potential in a host. Specifically, we examine in vivo thrombosis potential employing germ-free mice colonized with either high TMA-producing stable human fecal polymcrobial communities or a defined CutC-deficient background microbial community coupled with a CutC-expressing human commensal±genetic disruption of its cutC gene (ie, Clostridium sporogenes Δ cutC).Collectively, these studies point to the microbial choline TMA-lyase pathway as a rational molecular target for the treatment of atherothrombotic heart disease.
Predicting Malignancy Risk of Screen-Detected Lung Nodules–Mean Diameter or Volume
Authors: Martin Tammemagi, Alex J. Ritchie, Sukhinder Atkar-Khattra, Brendan Dougherty, Calvin Sanghera, John R. Mayo, Ren Yuan, Daria Manos, Annette M. McWilliams, Heidi Schmidt, Michel Gingras, Sergio Pasian, Lori Stewart, Scott Tsai, Jean M. Seely, Paul Burrowes, Rick Bhatia, Ehsan A. Haider, Colm Boylan, Colin Jacobs, Bram van Ginneken, Ming-Sound Tsao, Stephen Lam
Journal: Journal of Thoracic Oncology (2018)
Abstract 14591: A Common SCN5A Polymorphism H558R Modifies Clinical Phenotype of Brugada Syndrome by Modulating DNA Methylation of SCN5A Promoters
Authors: Hiroya Matsumura, Yukiko Nakano, Akinori Sairaku, Takehito Tokuyama, Shunsuke Tomomori, Michitaka Amioka, Naoya Hironobe, Yasuki Kihara
Journal: Circulation (2016)

Objectives: The common SCN5A polymorphism, rs1805124 (c.1673A>G, H558R), has been reported to improve the sodium channel activity in mutated channels and as a genetic modifier of Brugada syndrome (...
Cetuximab in combination with platinum-based chemotherapy or radiotherapy in patients with recurrent and/or metastatic SSCHN in clinical routine: Updated interim results of the prospective SOCCER study
Authors: M. Hecht, D. Hahn, P. Wolber, M. Hautmann, D. Reichert, J. Weniger, C. Belka, T. Bergmann, T. Göhler, M.K. Welslau, D. Hofmann, R. Fiektkau
Journal: Annals of Oncology (2018)
Oxygen therapy for acutely ill medical patients: a clinical practice guideline
Authors: Reed A C Siemieniuk, Derek K Chu, Lisa Ha-Yeon Kim, Maria-Rosa Güell-Rous, Waleed Alhazzani, Paola M Soccal, Paul J Karanicolas, Pauline D Farhoumand, Jillian L K Siemieniuk, Imran Satia, Elvis M Irusen, Marwan M Refaat, J Stephen Mikita, Maureen Smith, Dian N Cohen, Per O Vandvik, Thomas Agoritsas, Lyubov Lytvyn, Gordon H Guyatt
Journal: BMJ (2018)

### What you need to know

What is the best way to use oxygen therapy for patients with an acute medical illness? A systematic review published in the Lancet in April 2018 found that supplemental oxygen in inpatients with normal oxygen saturation increases mortality.1 Its authors concluded that oxygen should be administered conservatively, but they did not make specific recommendations on how to do it. An international expert panel used that review to inform this guideline. It aims to promptly and transparently translate potentially practice-changing evidence to usable recommendations for clinicians and patients.2 The panel used the GRADE framework and following standards for trustworthy guidelines.3

The panel asked;

The panel makes a strong recommendation for maintaining an oxygen saturation of no more than 96% in acutely ill medical patients (upper limit). The panel did not make a recommendation on when to start (the lower limit) for …
P1.17-06 Salvage Surgery After Chemotherapy and/or Radiotherapy Including SBRT and Proton: Consecutive Analysis of 46 Patients
Authors: A. Kobayashi, H. Horinouchi, Y. Nakayama, Y. Ohe, M. Yotsukura, S. Uchida, K. Asakura, Y. Yoshida, K. Nakagawa, S. Watanabe
Journal: Journal of Thoracic Oncology (2018)
OA01.02 The Estimate of Shrinking Field and SIB Radiotherapy Guided by 18F-FDG PET/CT in Locally Advanced NSCLC Patients: A Phase 2 Randomized Clinical
Authors: Y. Zhu, C. Jiang, F. Gu, Q. Lin, X. Sun, Y. Xu
Journal: Journal of Thoracic Oncology (2018)
Abstract 12243: Outcome in Takotsubo Cardiomyopathy: Not as Favorable as Expected?
Authors: Thomas Stiermaier, Steffen Desch, Gerhard Schuler, Holger Thiele, Ingo Eitel
Journal: Circulation (2014)

Introduction: Prognosis of patients with Takotsubo cardiomyopathy (TTC) is generally thought to be favorable. However, the initial presentation can be accompanied by various fatal complications and currently available outcome data are sparse. Therefore, the aim of the present study was to determine short-term and long-term mortality in a large cohort of patients with TTC. Methods: A total of 177 patients presenting with TTC were matched for age and gender with 177 ST-elevation myocardial infarction (STEMI) patients. Clinical follow-up was conducted with a standardized telephone follow-up and all events were centrally adjudicated. Results: Follow-up was available in 96.6% of patients after a median of 3.4 years. During the follow-up period, all-cause mortality was significantly higher in TTC patients as compared to the matched STEMI cohort (25.0% versus 16.1%, relative risk [RR] 1.55, 95% confidence interval [CI] 1.01 to 2.39, p=0.04). Cardiovascular mortality did not differ between the study groups. 28-da...
Prediction of irAEs in ipilimumab-treated melanoma patients based on serum autoantibodies
Authors: J.C. Hassel, J. Mangana, R. Dummer, C. Pföhler, K. Wistuba-Hamprecht, B. Weide, L. Hakim-Meibodi, F. Meier, J. Roth, H.-D. Zucht, P. Budde, M. Tuschen, P. Schulz-Knappe
Journal: Annals of Oncology (2018)
Sixty seconds on . . . baloxavir
Authors: Nigel Hawkes
Journal: BMJ (2018)

Quite right. Baloxavir marboxil (Xofluza) is a new drug for treating flu, approved by the US Food and Drug Administration in double quick time and ready for this year’s US flu season.

Actually, no better than oseltamivir (Tamiflu) in trials reported in the New England Journal of Medicine in September.1 Compared with a placebo, it …
Opportunistic bacteria confer the ability to ferment prebiotic starch in the adult cystic fibrosis gut
Authors: Yanan Wang, Lex E.X. Leong, Rebecca L. Keating, Tokuwa Kanno, Guy C.J. Abell, Fredrick M. Mobegi, Jocelyn M. Choo, Steve L. Wesselingh, A. James Mason, Lucy D. Burr, Geraint B. Rogers
Journal: Gut Microbes (2018)

Chronic disruption of the intestinal microbiota in adult cystic fibrosis (CF) patients is associated with local and systemic inflammation, and has been linked to the risk of serious comorbidities. Supplementation with high amylose maize starch (HAMS) might provide clinical benefit by promoting commensal bacteria and the biosynthesis of immunomodulatory metabolites. However, whether the disrupted CF gut microbiota has the capacity to utilise these substrates is not known. We combined metagenomic sequencing, in vitro fermentation, amplicon sequencing, and metabolomics to define the characteristics of the faecal microbiota in adult CF patients and assess HAMS fermentation capacity. Compared to healthy controls, the faecal metagenome of adult CF patients had reduced bacterial diversity and prevalence of commensal fermentative clades. In vitro fermentation models seeded with CF faecal slurries exhibited reduced acetate levels compared to healthy control reactions, but comparable levels of butyrate and propionate. While the commensal genus Faecalibacterium was strongly associated with short chain fatty acid (SCFA) production by healthy microbiota, it was displaced in this role by Clostridium sensu stricto 1 in the microbiota of CF patients. A subset of CF reactions exhibited enterococcal overgrowth, resulting in lactate accumulation and reduced SCFA biosynthesis. The addition of healthy microbiota to CF faecal slurries failed to displace predominant CF taxa, or substantially influence metabolite biosynthesis. Despite significant microbiota disruption, the adult CF gut microbiota retains the capacity to exploit HAMS. Our findings highlight the potential for taxa associated with the altered CF gut microbiotato mediate prebiotic effects in microbial systems subject to ongoing perturbation, irrespective of the depletion of common commensal clades.
Validation of the MammaTyper® pathological complete response (pCR)-score as a predictor for response after neoadjuvant chemotherapy (NACT) in patients with early breast cancer (BC)
Authors: P.A. Fasching, M. Laible, K.E. Weber, R.M. Wirtz, C. Denkert, K. Schlombs, S. Schmatloch, O. Camara, H.J. Lück, J. Huober, T. Karn, M.T. van Mackelenbergh, F. Marme, V. Müller, C. Schem, E. Stickeler, U. Sahin, S. Loibl, M. Untch
Journal: Annals of Oncology (2018)
P2.11-16 Comparison of Two Lung Cancer Screening Programs in One Medical Center - Does Experience of the Screening Team and Indications Affect the Results?
Authors: M. Ostrowski, T. Marjanski, R. Dziedzic, M. Jelitto-Gorska, K. Dziadziuszko, W. Rzyman
Journal: Journal of Thoracic Oncology (2018)
Striking dyserythropoiesis in sickle cell anemia following an aplastic crisis
Authors: Anna Austin, Kirstin Lund, Barbara J. Bain
Journal: American Journal of Hematology (2018)

A chest X-ray demonstrated right sided consolidation. An echocardiogram showed mild mitral regurgitation and tricuspid regurgitation with a dilated left ventricle and mildly reduced ventricular function. Infection screening including urine legionella and pneumococcal antigen, blood cultures, urine cultures, and viral respiratory screen were all negative. The patient was intubated and ventilated shortly after arrival in the pediatric intensive care unit. He improved clinically over the next few days following further red cell transfusion and escalation of antibiotics, and was extubated. Serum troponin gradually normalized. As he recovered, there was an outpouring of nucleated red blood cells into the peripheral blood, with striking dyserythropoiesis. Erythroblasts showed nuclear lobulation, basophilic stippling, detached nuclear fragments, occasional binucleated forms, and occasional mitotic figures (Images). Parvovirus B19 serology, immunoglobulin (Ig)G and IgM, was positive, confirming recent parvovirus infection. Thus the suspected diagnosis of parvovirus-induced severe aplastic crisis was confirmed, this being complicated by pneumonia and by cardiac ischemia secondary to severe anemia. Dyserythropoiesis has many causes, including hemolytic anemia. When erythropoiesis is very active—“stress erythropoiesis”—dyserythropoiesis can be striking, as in this patient. It is important to be aware of the many potential causes of dyserythropoiesis in order to avoid misdiagnosis. Nothing to report.
Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC): Initial results of an expansion cohort from FORWARD II, a phase Ib study
Authors: U.A. Matulonis, K.N. Moore, L.P. Martin, I.B. Vergote, C. Castro, L. Gilbert, K. Malek, M.J. Birrer, D.M. O’Malley
Journal: Annals of Oncology (2018)
P2.13-24 Prospective Efficacy of Osimertinib in Circulating Tumour DNA (ctDNA) T790M-Mutant NSCLC Patients
Authors: J. Remon, C. Jovelet, L. Lacroix, D. Planchard, L. Mezquita, K. Howarth, E. Green, V. Plagnol, C. Morris, N. Rosenfeld, C. Caramella, C. Lepéchoux, F. Aboubakar Nana, A. Botticella, J. Adam, R. Ferrara, A. Gazzah, M. Ngocamus, J. Soria, B. Besse
Journal: Journal of Thoracic Oncology (2018)
RETRACTED ARTICLE: Tumour-originated exosomal miR-155 triggers cancer-associated cachexia to promote tumour progression
Authors: Qi Wu, Si Sun, Zhiyu Li, Qian Yang, Bei Li, Shan Zhu, Lijun Wang, Juan Wu, Jingping Yuan, Changhua Yang, Juanjuan Li, Shengrong Sun
Journal: Molecular Cancer (2018)

Abstract Emerging evidence supports the pivotal roles of cancer-associated cachexia in breast cancer progression. However, the mediators and mechanisms that mediate cancer-induced cachexia remain unclear. Here, we show that breast cancer-derived exosomes alter adipocytes and muscle cells in terms of increased catabolism characterized by the release of metabolites. Likewise, tumour cells cocultivated with mature adipocytes or C2C12 exhibit an aggressive phenotype through inducing epithelial-mesenchymal transition. Mechanistically, we show that cancer cell-secreted miR-155 promotes beige/brown differentiation and remodel metabolism in resident adipocytes by downregulating the PPARγ expression, but does not significantly affect biological conversion in C2C12. In vitro the use of propranolol ameliorates tumour exosomes-associated cachectic wasting through upregulating the PPARγ expression. These results demonstrate that cancer-derived exosomes reprogram systemic energy metabolism and accelerate cancer-associated cachexia to facilitate tumour progression.
Dose-determination results from a phase Ib/II study of ceritinib (CER) + ribociclib (RIB) in ALK-positive (ALK+) non-small cell lung cancer (NSCLC)
Authors: A. Santoro, W.-C. Su, A. Navarro, M. Simonelli, J.C.-H. Yang, A. Ardizzoni, F. Barlesi, J.H. Kang, S. Didominick, A. Abdelhady, B. Goswami, A. Crystal, E. Felip
Journal: Annals of Oncology (2018)
Association of Psoriasis With Inflammatory Bowel Disease
Authors: Yun Fu, Cheng-Han Lee, Ching-Chi Chi
Journal: JAMA Dermatology (2018)

Patients with psoriasis may experience comorbidities involving cardiovascular diseases, chronic kidney disease, uveitis, psychiatric disturbances, and metabolic syndrome. However, the association between psoriasis and inflammatory bowel disease (IBD) has been largely unclear.To investigate the association of psoriasis with IBD.For this systematic review and meta-analysis, MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched for relevant studies from inception to January 17, 2018.Case-control, cross-sectional, or cohort studies that examined either the odds or risk of IBD in patients with psoriasis were included. No geographic or language limitations were used in the search.The PRISMA and MOOSE guidelines were followed for data extraction. The Newcastle-Ottawa Scale was used to evaluate the risk of bias of included studies. Crohn disease and ulcerative colitis were analyzed separately and random-effects model meta-analysis was conducted. A subgroup analysis was performed on psoriatic arthritis.The risk and odds of IBD, Crohn disease, and ulcerative colitis in patients with psoriasis.A total of 5 case-control or cross-sectional studies and 4 cohort studies with 7 794 087 study participants were included. Significant associations were found between psoriasis and Crohn disease (odds ratio, 1.70; 95% CI, 1.20-2.40) and between psoriasis and ulcerative colitis (odds ratio, 1.75; 95% CI, 1.49-2.05). Patients with psoriasis had an increased risk of Crohn disease (risk ratio, 2.53; 95% CI, 1.65-3.89) and ulcerative colitis (risk ratio, 1.71; 95% CI, 1.55-1.89).These findings suggest that psoriasis is significantly associated with IBD. Gastroenterology consultation may be indicated when patients with psoriasis present with bowel symptoms.
P1.09-17 CTNNB1 (Beta-Catenin) Mutations in Non-Small Cell Lung Carcinoma: A Clinicopathological Study of 18 Cases
Authors: V. Thomas De Montpréville, R. El Ayoubi, M. Mamodaly, L. Lacroix, O. Mercier, E. Fadel, B. Besse, M. Ghigna
Journal: Journal of Thoracic Oncology (2018)
P2.04-05 Correlation Between PD-L1 Gene Promoter Polymorphisms and Expression of PD-L1 mRNA and Protein in NSCLC Patients.
Authors: T. Kucharczyk, A. Grenda, P. Krawczyk, M. Nicoś, B. Jarosz, J. Szumiło, K. Reszka, T. Trojanowski, J. Milanowski
Journal: Journal of Thoracic Oncology (2018)
Clinical Metagenomic Next-Generation Sequencing for Pathogen Detection
Authors: Wei Gu, Steve Miller, Charles Y. Chiu
Journal: Annual Review of Pathology Mechanisms of Disease (2018)

Nearly all infectious agents contain DNA or RNA genomes, making sequencing an attractive approach for pathogen detection. The cost of high-throughput or next-generation sequencing has been reduced by several orders of magnitude since its advent in 2004, and it has emerged as an enabling technological platform for the detection and taxonomic characterization of microorganisms in clinical samples from patients. This review focuses on the application of untargeted metagenomic next-generation sequencing to the clinical diagnosis of infectious diseases, particularly in areas in which conventional diagnostic approaches have limitations. The review covers ( a) next-generation sequencing technologies and common platforms, ( b) next-generation sequencing assay workflows in the clinical microbiology laboratory, ( c) bioinformatics analysis of metagenomic next-generation sequencing data, ( d) validation and use of metagenomic next-generation sequencing for diagnosing infectious diseases, and ( e) significant case reports and studies in this area. Next-generation sequencing is a new technology that has the promise to enhance our ability to diagnose, interrogate, and track infectious diseases.
Evaluation of chemotherapy response score and lymphocytic infiltration as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy
Authors: M. Liontos, M. Sotiropoulou, M. Kaparelou, K. Tzannis, G. Tsironis, A. Kyriazoglou, A. Tsiara, R. Zakopoulou, K. Koutsoukos, F. Zagouri, D. Vlachos, N. Thomakos, D. Haidopoulos, A. Rodolakis, M.A.C. Dimopoulos, A. Bamias
Journal: Annals of Oncology (2018)
Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations
Authors: B.J. Solomon, J.-F. Martini, S.-H.I. Ou, R. Chiari, R.A. Soo, A. Bearz, S. Li, H. Thurm, C.-C. Lin, G.J. Riely, T.M. Bauer, A.T. Shaw
Journal: Annals of Oncology (2018)
Phase Ib/IIa study of RX-5902, a novel orally bioavailable inhibitor of phosphorylated P68, which prevents nuclear β-catenin translocation in patients with triple negative breast cancer
Authors: J.R. Diamond, E. Andreopoulou, A.M. Favret, R. Nanda, C. Peterson, E. Benaim
Journal: Annals of Oncology (2018)
Responses and durability of clinical benefit in non-small cell lung cancer treated with pegilodecakin in combination with anti-PD-1 inhibitors
Authors: E.B. Garon, D.J. Wong, J.G. Schneider, R. Aljumaily, W.M. Korn, M.R. Patel, K.A. Autio, K.P. Papadopoulos, A. Naing, N. Gabrail, P.N. Munster, J. Goldman, A. Hung, M. Oft, J. Leveque, D.R. Spigel
Journal: Annals of Oncology (2018)
OA13.02 Two Novel Immunotherapy Agents Targeting DLL3 in SCLC: Trials in Progress of AMG 757 and AMG 119
Authors: T. Owonikoko, M. Smit, H. Borghaei, R. Salgia, M. Boyer, E. Rasmussen, L. Byers
Journal: Journal of Thoracic Oncology (2018)
Prediction modelling using routine clinical parameters to stratify survival in Malignant Pleural Mesothelioma patients undergoing cytoreductive surgery
Authors: Edward J.A. Harris, Steven Kao, Brian McCaughan, Takashi Nakano, Nobuyuki Kondo, Rebecca Hyland, Anna K. Nowak, Nicholas H. de Klerk, Fraser J.H. Brims
Journal: Journal of Thoracic Oncology (2018)
Patterns of recurrence to Osimertinib in T790m positive NSCLC: A Swiss cohort study
Authors: S. Schmid, D. Klingbiel, S. Aeppli, C. Britschgi, O. Gautschi, M. Pless, S.I. Rothschild, L. Wannesson De Nicola, W.-D. Janthur, D. Foerbs, I. Demmer, W. Jochum, M. Früh
Journal: Annals of Oncology (2018)
First-in-human trial design for W0101: A first-in-class antibody-drug conjugate targeting IGF-1R and identification of the target patient population
Authors: C.A. Gomez-Roca, E. Garralda-Cabanas, F. Cruzalegui, F. Ausseil, G. Zorza, O. Delfour, J. Besse, B. Akla, S. Gautier, J. Adam, M. Lacroix-Triki, A. Passioukov, R. Roche, M. Pavlyuk, C. Massard
Journal: Annals of Oncology (2018)
P1.01-52 BR-34- Randomized Trial of Durvalumab and Tremelimumab +/- Platinum Chemotherapy in Patients with Metastatic Squamous or Non-Squamous NSCLC
Authors: S. Kulkarni, S. Laurie, G. Goss, F. Perrone, B. Hughes, N. Pavlakis, M. Stockler, A. Blais, L. Zibdawi, F. Vera – Badillo, N. Leighl
Journal: Journal of Thoracic Oncology (2018)
P2.04-04 Expression of Intratumoral Programmed Cell Death-Ligand 1 (PD-L1) and Intratumoral CD4+T Cell, CD8+T Cell and FOXP3+T Cell in Lung Cancer
Authors: Y. Jin, H. Shimada, S. Yamauchi, N. Inase, O. Matsubara
Journal: Journal of Thoracic Oncology (2018)
EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment
Authors: M. Martín, W. Eiermann, H.S. Rugo, J. Ettl, S.A. Hurvitz, A. Gonçalves, R. Yerushalmi, D. Markova, I.C. Tudor, J.L. Blum, A.L. Hannah, J.K. Litton
Journal: Annals of Oncology (2018)